July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Visual Impairment, Multi-Morbidity and Their Association with Short Term Mortality
Author Affiliations & Notes
  • David J Lee
    Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Dandan Diane Zheng
    Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Sharon L Christ
    Purdue University, West Lafayette, Indiana, United States
  • Byron L Lam
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Laura A McClure
    Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   David Lee, None; Dandan Zheng, None; Sharon Christ, None; Byron Lam, None; Laura McClure, None
  • Footnotes
    Support  NIH F31 EY025936
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4460. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David J Lee, Dandan Diane Zheng, Sharon L Christ, Byron L Lam, Laura A McClure; Visual Impairment, Multi-Morbidity and Their Association with Short Term Mortality. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4460.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Visual impairment (VI) is among the most disabling conditions. VI and visual disorders often co-occur with other disabling chronic conditions. This research identifies chronic disease patterns and their relationship to VI and estimates the associated mortality risk in a national representative population.

Methods : Using data from 27,731 participants aged 18 years and older of the 2009 National Health Interview Survey, we employed latent class analysis (LCA) to identify subgroups of participants based on their combination of chronic illnesses; 14 self-reported disease/conditions including visual impairment were utilized. Mortality linkage with National Death Index was performed through December 31, 2011. Survival analyses were conducted to assess how the derived latent class membership predicted short-term mortality.

Results : LCA identified 5 different groups with 70% of participants belonging to the healthy group with low chronic disease prevalence. The other four groups represented various degrees and patterns of multi-morbidity and were labeled accordingly: 10.9% population belongs to the “mildly impaired group” with a 59% chance of arthritis and 20% of VI; 13.6% belong to the “hypertensive diabetic group” with high prevalence of hypertension (87%) and diabetes (43%) and a 12.6% chance of VI; 3.0% are in “heart disease group” with high chance of coronary heart disease (93%) or myocardial infarction (50%), and 2.2% belong to the “severely impaired group” with 83% chance of arthritis, 60% of hearing impairment and 40% of VI. 647 deaths were identified with average follow-up time of 2.5 years. After controlling for survey design, age, gender, race, Hispanic origin, education, BMI, smoking and alcohol drinking status, compared to the healthy group, participants in four latent groups had elevated mortality risk: heart disease group Hazard Ratio (HR) 2.04 (95% confidence interval [1.42, 2.91]); hypertensive & diabetic group (1.54 [1.15, 2.06]); mildly impaired group (1.83 [1.35, 2.48]); and severely impaired group (3.80 [2.46, 5.85]).

Conclusions : VI contributed to membership in 3 of 4 distinct multi-morbidity groups collectively representing 25% of the US population. The prevalence rate of VI was highest in the severely impaired group (40%) which also had the highest hazard for mortality (3.8). Clinicians should be aware that patients with VI may also have other chronic conditions that may impact mortality risk.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×